Moreover, mature DCs (CD45+CD11c+CD80+CD86+) within the tumors were analyzed by flow cytometry after the third treatment, revealing a higher proportion in the MNs (TDEVs@OVs)‐treated group, indicative of enhanced recruitment and maturation of DCs crucial for activating tumor‐specific T cells (Figure 5c–5d and Figure S24). This evidence concerns the gene CD86 and neoplasm.